{
  "individual_results": [
    {
      "question": "What is the clinical role of Flumazenil, and how does its method of administration differ from that of Lepirudin?",
      "gt_answer": "Flumazenil is used to reverse the effects of benzodiazepine sedation and is typically administered intravenously due to its low oral bioavailability. In contrast, Lepirudin, another drug listed in the \"drugbank-drug\" table, is a liquid form that Bayer ceased producing in 2012. While the passage discusses Flumazenil's role and preferred administration route, the table provides details about Lepirudin's state and production history.",
      "system_answer": "Flumazenil is clinically used as a benzodiazepine antagonist to reverse sedation. It is typically administered intravenously to rapidly counteract the effects of benzodiazepines. Lepirudin is an anticoagulant used for the treatment of heparin-induced thrombocytopenia and can be administered either intravenously or subcutaneously.",
      "gt_sources": [
        "Target-8693922",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-12571811",
        "pubmed-targets/Target-19567673",
        "pubmed-targets/Target-15686733",
        "pubmed-targets/Target-17689532",
        "pubmed-targets/Target-15161930"
      ],
      "metrics": {
        "rouge1": 0.3738317757009346,
        "rouge2": 0.15238095238095237,
        "rougeL": 0.28037383177570097,
        "string_similarity": 0.20392156862745098,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 12.292829513549805,
        "llm_correctness": 0.8
      }
    },
    {
      "question": "How does the classification of Flumazenil as an imidazobenzodiazepine compare to the classification of Cetuximab?",
      "gt_answer": "Flumazenil is an imidazobenzodiazepine, which is a benzodiazepine antagonist used to reverse the effects of benzodiazepines. Cetuximab, on the other hand, is categorized as a biotech drug in the DrugBank database, specifically an epidermal growth factor receptor binding FAB used for other therapeutic purposes.",
      "system_answer": "Flumazenil is classified as an imidazobenzodiazepine, which is a chemical class associated with benzodiazepine antagonists, whereas Cetuximab is classified as a chimeric (mouse/human) monoclonal antibody targeting the epidermal growth factor receptor (EGFR). These classifications are fundamentally different, with Flumazenil being a small molecule drug acting on the central nervous system and Cetuximab being a biologic used as an antineoplastic agent.",
      "gt_sources": [
        "Target-8693922",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-19567673",
        "pubmed-targets/Target-15686733",
        "pubmed-targets/Target-14520122",
        "pubmed-targets/Target-15161930",
        "pubmed-targets/Target-23494984"
      ],
      "metrics": {
        "rouge1": 0.4380952380952381,
        "rouge2": 0.2135922330097087,
        "rougeL": 0.3619047619047619,
        "string_similarity": 0.1437908496732026,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 11.250455617904663,
        "llm_correctness": 0.9
      }
    },
    {
      "question": "What is the mechanism of action of Flumazenil, and how does it differ from that of Denileukin diftitox?",
      "gt_answer": "Flumazenil acts as a specific competitive antagonist at benzodiazepine receptors, reversing the effects of benzodiazepines. Denileukin diftitox, according to the \"drugbank-drug\" table, is a recombinant DNA-derived cytotoxic protein composed of diphtheria toxin fragments and interleukin-2, indicating a different mechanism of action involving cytotoxicity rather than receptor antagonism.",
      "system_answer": "Flumazenil acts as a benzodiazepine receptor antagonist, reversing the effects of benzodiazepines by competitively inhibiting their binding at the GABA-A receptor. In contrast, Denileukin diftitox is a fusion protein composed of interleukin-2 and diphtheria toxin, which targets cells expressing the high-affinity IL-2 receptor, leading to cell death through the inhibition of protein synthesis. These mechanisms highlight Flumazenil's role in modulating GABAergic activity versus Denileukin diftitox's targeted cytotoxic approach.",
      "gt_sources": [
        "Target-8693922",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-15686733",
        "pubmed-targets/Target-10870987",
        "pubmed-targets/Target-15161930",
        "pubmed-targets/Target-12657846",
        "pubmed-targets/Target-23494984"
      ],
      "metrics": {
        "rouge1": 0.532258064516129,
        "rouge2": 0.22950819672131148,
        "rougeL": 0.3709677419354839,
        "string_similarity": 0.19804134929270947,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 13.32912564277649,
        "llm_correctness": 1.0
      }
    },
    {
      "question": "How does the administration route of Flumazenil influence its clinical application, and how does this compare to the state and administration characteristics of Etanercept?",
      "gt_answer": "Flumazenil is administered intravenously due to its low bioavailability when taken orally, which is crucial for its role in quickly reversing benzodiazepine sedation. Etanercept, listed in the \"drugbank-drug\" table, is a liquid administered in a different manner as it is a dimeric fusion protein used for other therapeutic indications, demonstrating that the state and administration route of a drug are tailored to its specific clinical use.",
      "system_answer": "Flumazenil is generally administered intravenously, allowing for rapid onset of action, which is crucial in clinical emergencies like reversing benzodiazepine overdose. This aligns with its use in acute settings where quick CNS action is required. In contrast, Etanercept is administered subcutaneously, suitable for chronic conditions such as rheumatoid arthritis, providing a slower absorption and sustained release, which is beneficial for long-term management rather than immediate intervention.",
      "gt_sources": [
        "Target-8693922",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-15272053",
        "pubmed-targets/Target-19567673",
        "pubmed-targets/Target-15963001",
        "pubmed-targets/Target-15686733",
        "pubmed-targets/Target-23468867",
        "pubmed-targets/Target-17689532",
        "pubmed-targets/Target-8573632",
        "pubmed-targets/Target-10067800",
        "pubmed-targets/Target-8417277",
        "pubmed-targets/Target-15161930",
        "pubmed-targets/Target-19637941",
        "pubmed-targets/Target-9497025"
      ],
      "metrics": {
        "rouge1": 0.373134328358209,
        "rouge2": 0.09090909090909091,
        "rougeL": 0.23880597014925373,
        "string_similarity": 0.08492569002123142,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 68.83345556259155,
        "llm_correctness": 0.9
      }
    },
    {
      "question": "What are the therapeutic uses of Flumazenil, and how do they differ from those of Dornase alfa?",
      "gt_answer": "Flumazenil is used for reversing benzodiazepine-induced sedation, terminating benzodiazepine-induced anesthesia, and restoring spontaneous respiration and consciousness in intensive care patients. Dornase alfa, according to the \"drugbank-drug\" table, is a biosynthetic form of human deoxyribonuclease I used to reduce sputum viscosity in cystic fibrosis patients, highlighting a distinct therapeutic indication compared to Flumazenil.",
      "system_answer": "Flumazenil is primarily used as an antidote for benzodiazepine overdose, reversing their sedative effects, and occasionally to diagnose benzodiazepine dependency. In contrast, Dornase alfa is used in the treatment of cystic fibrosis, where it helps break down DNA in thick mucus, improving lung function and reducing respiratory infections. These uses differ in that Flumazenil is used mainly for acute care in overdose situations, while Dornase alfa is part of long-term management for a chronic condition.",
      "gt_sources": [
        "Target-8693922",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-10417493",
        "pubmed-targets/Target-15080795",
        "pubmed-targets/Target-19567673",
        "pubmed-targets/Target-15686733",
        "pubmed-targets/Target-15161930"
      ],
      "metrics": {
        "rouge1": 0.36641221374045796,
        "rouge2": 0.06201550387596899,
        "rougeL": 0.22900763358778625,
        "string_similarity": 0.048884165781083955,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 10.632875204086304,
        "llm_correctness": 0.9
      }
    },
    {
      "question": "What similar target organism is shared by drugs with the same target organism as Valdecoxib?",
      "gt_answer": "The passage mentions both humans and rats as target organisms for the study of Valdecoxib. In the drugbank-targets table, several targets, such as the Epidermal growth factor receptor, also list humans as the target organism, which is common in the study and application of many therapeutic drugs.",
      "system_answer": "Drugs that share a similar target organism as Valdecoxib, which targets COX-2 in humans, include other COX-2 inhibitors that are also used to treat inflammation in humans.",
      "gt_sources": [
        "Target-10715145",
        "drugbank-targets"
      ],
      "system_sources": [
        "pubmed-targets/Target-9297727",
        "pubmed-targets/Target-10715145",
        "pubmed-targets/Target-8937457",
        "pubmed-targets/Target-25376919",
        "pubmed-targets/Target-11587492"
      ],
      "metrics": {
        "rouge1": 0.31168831168831174,
        "rouge2": 0.02666666666666666,
        "rougeL": 0.15584415584415587,
        "string_similarity": 0.05982905982905983,
        "source_precision": 0.2,
        "source_recall": 0.5,
        "source_f1": 0.28571428571428575,
        "processing_time": 13.555781602859497,
        "llm_correctness": 0.5
      }
    },
    {
      "question": "What is the primary modification site of human serum albumin when modified by amoxicillin in ex vivo samples, and is amoxicillin included in the drug databases?",
      "gt_answer": "The primary modification site of human serum albumin (HSA) when modified by amoxicillin (AX) in ex vivo samples is Lys 190. However, amoxicillin is not listed in the provided DrugBank tables, which focus on biotech drugs.",
      "system_answer": "The primary modification site of human serum albumin when modified by amoxicillin in ex vivo samples is not provided in the documents. Additionally, the documents do not confirm whether amoxicillin is included in any drug databases.",
      "gt_sources": [
        "Target-25088930",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-7632160",
        "pubmed-targets/Target-11325810",
        "pubmed-targets/Target-18805433",
        "pubmed-targets/Target-7879937",
        "pubmed-targets/Target-15255802",
        "pubmed-targets/Target-18486039",
        "drugbank-drug_trans_articles.csv",
        "pubmed-targets/Target-10725273"
      ],
      "metrics": {
        "rouge1": 0.6666666666666666,
        "rouge2": 0.4857142857142857,
        "rougeL": 0.5833333333333334,
        "string_similarity": 0.5121412803532008,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 69.14406251907349,
        "llm_correctness": 0.0
      }
    },
    {
      "question": "What analytical techniques were used in the study to investigate amoxicillin's effect on human serum albumin, and are these techniques relevant to the analysis of other drugs?",
      "gt_answer": "The study employed multiple reaction monitoring (MRM), precursor ion scan (PIS), and high-resolution MS systems such as LTQ Orbitrap XL to investigate amoxicillin's effect on human serum albumin. These advanced analytical techniques are relevant to the analysis of biotech drugs listed in the DrugBank tables, such as Cetuximab and Lepirudin, which also require precise analytical methodologies for their characterization and quality control.",
      "system_answer": "The study on amoxicillin's effect on human serum albumin likely employed analytical techniques that are broadly applicable in pharmacological research. Although the documents do not directly address the specific techniques used for amoxicillin, they mention methods such as in vitro assays, cytochrome P450 enzyme studies, and microsomal metabolism assays, which are relevant for analyzing drug-protein interactions. These techniques are commonly used in drug studies and could be adapted for investigating amoxicillin's interaction with human serum albumin.",
      "gt_sources": [
        "Target-25088930",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-7632160",
        "pubmed-targets/Target-11325810",
        "pubmed-targets/Target-18805433",
        "pubmed-targets/Target-7879937",
        "pubmed-targets/Target-22859722",
        "drugbank-drug_trans_articles.csv"
      ],
      "metrics": {
        "rouge1": 0.36363636363636365,
        "rouge2": 0.1702127659574468,
        "rougeL": 0.27972027972027974,
        "string_similarity": 0.116,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 82.93402647972107,
        "llm_correctness": 0.0
      }
    },
    {
      "question": "What are the IC50 values for nifedipine in blocking T-type and L-type Ca2+ channel currents, and is nifedipine included in any comprehensive drug database?",
      "gt_answer": "The IC50 values for nifedipine in blocking T-type and L-type Ca2+ channel currents are 1.2 micromol/l and 0.14 nmol/l, respectively. However, nifedipine is not included in the sample rows of the drugbank-drug table provided.",
      "system_answer": "The provided documents do not contain specific information regarding the IC50 values for nifedipine in blocking T-type and L-type Ca2+ channel currents, nor do they mention whether nifedipine is included in any comprehensive drug database.",
      "gt_sources": [
        "Target-16899990",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-17030912",
        "pubmed-targets/Target-8063004",
        "drugbank-enzymes_polypeptides_pfams.csv",
        "pubmed-targets/Target-10901704",
        "pubmed-targets/Target-17723160",
        "pubmed-targets/Target-8667235",
        "pubmed-targets/Target-26381793",
        "pubmed-targets/Target-16584282",
        "pubmed-targets/Target-11324464"
      ],
      "metrics": {
        "rouge1": 0.5897435897435899,
        "rouge2": 0.4210526315789474,
        "rougeL": 0.5128205128205128,
        "string_similarity": 0.4060475161987041,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 71.4234766960144,
        "llm_correctness": 0.0
      }
    },
    {
      "question": "What organism is associated with the target of the drug identified as DB00001, and how does this relate to any of the calcium channel blockers mentioned?",
      "gt_answer": "The organism associated with the target of the drug with primary_key DB00001 (Lepirudin) is humans. This does not directly relate to any of the calcium channel blockers (efonidipine, nifedipine, mibefradil) discussed in the passage.",
      "system_answer": "The drug identified as DB00001 is associated with the organism *Homo sapiens* (human). However, there is no direct information linking DB00001 to calcium channel blockers. Calcium channel blockers typically target human calcium channels, but the specific target or mechanism of action for DB00001 is not detailed in the provided evidence.",
      "gt_sources": [
        "Target-16899990",
        "drugbank-targets"
      ],
      "system_sources": [
        "drugbank-drug_pharmacology.csv",
        "drugbank-drug_reactions.csv",
        "drugbank-drug_targ_articles.csv",
        "pubmed-targets/Target-8312688",
        "drugbank-targets.csv",
        "drugbank-drug_classifications.csv",
        "pubmed-targets/Target-8667235",
        "pubmed-targets/Target-26381793",
        "drugbank-drug_affected_organisms.csv",
        "drugbank-targets_polypeptides_go.csv",
        "pubmed-targets/Target-19204080",
        "pubmed-targets/Target-16048994"
      ],
      "metrics": {
        "rouge1": 0.44705882352941173,
        "rouge2": 0.1686746987951807,
        "rougeL": 0.25882352941176473,
        "string_similarity": 0.07719298245614035,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 90.04175686836243,
        "llm_correctness": 1.0
      }
    },
    {
      "question": "Are any of the calcium channel blockers identified as biotech drugs?",
      "gt_answer": "None of the calcium channel blockers discussed in the passage (efonidipine, nifedipine, mibefradil) appear in the sample rows of the drugbank-drug table as biotech drugs.",
      "system_answer": "There is no evidence from the provided documents to suggest that any calcium channel blockers have been identified as biotech drugs.",
      "gt_sources": [
        "Target-16899990",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-17030912",
        "pubmed-targets/Target-17023693",
        "pubmed-targets/Target-21175441",
        "pubmed-targets/Target-10901704",
        "pubmed-targets/Target-8667235",
        "pubmed-targets/Target-26381793",
        "pubmed-targets/Target-19204080",
        "pubmed-targets/Target-16048994"
      ],
      "metrics": {
        "rouge1": 0.2978723404255319,
        "rouge2": 0.17777777777777778,
        "rougeL": 0.2978723404255319,
        "string_similarity": 0.4105960264900662,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 17.047098636627197,
        "llm_correctness": 0.8
      }
    },
    {
      "question": "Which human transporter is associated with the multidrug resistance of adrenocortical carcinoma, and what is the effect of mitotane on this transporter?",
      "gt_answer": "The human transporter implicated in the multidrug resistance of adrenocortical carcinoma is P-glycoprotein 1 (P-gp). The passage suggests that mitotane may have a direct action on P-gp, potentially reducing its activity and consequently decreasing chemoresistance, although the known action from the table is listed as \"unknown.\"",
      "system_answer": "There is no specific information available in the provided documents regarding the human transporter associated with multidrug resistance in adrenocortical carcinoma or the effect of mitotane on this transporter.",
      "gt_sources": [
        "Target-25096913",
        "drugbank-transporters"
      ],
      "system_sources": [
        "pubmed-targets/Target-16766716",
        "pubmed-targets/Target-11136295",
        "pubmed-targets/Target-17200836",
        "pubmed-targets/Target-21532165",
        "pubmed-targets/Target-11118042",
        "pubmed-targets/Target-17274666",
        "pubmed-targets/Target-1191483",
        "pubmed-targets/Target-14576130",
        "pubmed-targets/Target-15319333",
        "pubmed-targets/Target-18311418",
        "pubmed-targets/Target-11027924",
        "pubmed-targets/Target-14502105",
        "pubmed-targets/Target-15233703",
        "pubmed-targets/Target-22117616",
        "pubmed-targets/Target-11069211",
        "pubmed-targets/Target-9744552",
        "pubmed-targets/Target-9100971"
      ],
      "metrics": {
        "rouge1": 0.358974358974359,
        "rouge2": 0.13157894736842105,
        "rougeL": 0.25641025641025644,
        "string_similarity": 0.04805914972273567,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 35.39974808692932,
        "llm_correctness": 0.0
      }
    },
    {
      "question": "Can you identify a drug that is known to be produced using recombinant DNA technology, similar to the study's use of recombinant technology in Xenopus laevis oocytes?",
      "gt_answer": "Dornase alfa is a drug produced using recombinant DNA technology in genetically modified Chinese hamster ovary (CHO) cells, which is similar to the study's use of recombinant technology in Xenopus laevis oocytes to express Oat1 for studying the transport of mercapturic acids.",
      "system_answer": "Human Recombinant alpha-L-iduronidase (Laronidase) is a drug known to be produced using recombinant DNA technology, similar to the technology used in the study involving Xenopus laevis oocytes.",
      "gt_sources": [
        "Target-11641438",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-17044574",
        "drugbank-drug_international_brands.csv",
        "pubmed-targets/Target-17531625",
        "pubmed-targets/Target-2123741",
        "pubmed-targets/Target-10421612",
        "drugbank-drug_dosages.csv",
        "drugbank-drug_food_interactions.csv",
        "pubmed-targets/Target-2729995",
        "drugbank-drug_syn.csv"
      ],
      "metrics": {
        "rouge1": 0.5833333333333334,
        "rouge2": 0.3142857142857143,
        "rougeL": 0.4444444444444444,
        "string_similarity": 0.20042643923240938,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 21.958037614822388,
        "llm_correctness": 0.5
      }
    },
    {
      "question": "What is the significance of the selectivity of second-generation antihistamines for the H(1) receptor compared to other target proteins?",
      "gt_answer": "The high selectivity of second-generation antihistamines for the H(1) receptor enhances their efficacy in treating allergic conditions while minimizing side effects, contrasting with the varied target proteins like the Epidermal Growth Factor Receptor and Complement C1q subcomponents found in other drugs listed in the drugbank-targets table, which can lead to broader systemic effects.",
      "system_answer": "The significance of the selectivity of second-generation antihistamines for the H(1) receptor compared to other target proteins lies in their ability to effectively alleviate allergic symptoms while minimizing side effects associated with non-specific receptor binding. Second-generation antihistamines are designed to selectively target the H(1) receptor, which reduces histamine-induced allergic reactions without significantly affecting other receptors. This selectivity results in fewer side effects, such as sedation, that are common with first-generation antihistamines which can interact with a variety of receptors. This makes second-generation antihistamines preferable for long-term management of allergic conditions.",
      "gt_sources": [
        "Target-18336052",
        "drugbank-targets"
      ],
      "system_sources": [
        "pubmed-targets/Target-1799934",
        "pubmed-targets/Target-1549935",
        "drugbank-drug_targ_articles.csv",
        "pubmed-targets/Target-10223928",
        "pubmed-targets/Target-16357952",
        "pubmed-targets/Target-19596878",
        "pubmed-targets/Target-15665994",
        "pubmed-targets/Target-28106668"
      ],
      "metrics": {
        "rouge1": 0.4129032258064516,
        "rouge2": 0.19607843137254902,
        "rougeL": 0.3225806451612903,
        "string_similarity": 0.1400359066427289,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 45.28301811218262,
        "llm_correctness": 0.8
      }
    },
    {
      "question": "How does the development of second-generation antihistamines address the adverse effects associated with first-generation agents, and how does this compare with the descriptions of biotech drugs?",
      "gt_answer": "Second-generation antihistamines such as desloratadine, fexofenadine, and levocetirizine were developed to reduce adverse effects, particularly CNS-related ones, which were more common with first-generation agents. This is achieved through high selectivity for the H(1) receptor and minimal drug-drug interactions. In contrast, biotech drugs listed in the drugbank-drug table, such as Etanercept and Cetuximab, have complex mechanisms and targets, potentially leading to more varied side effects.",
      "system_answer": "The development of second-generation antihistamines specifically aimed to reduce the adverse effects associated with first-generation agents, such as sedation and cognitive impairment, by being more selective for peripheral H1-receptors and less likely to penetrate the central nervous system. This design reduces central sedative side effects. Similarly, biotech drugs are engineered to target specific disease-related antigens, often minimizing adverse reactions by sparing normal cells, akin to the specificity seen in second-generation antihistamines. Both strategies demonstrate a trend in pharmaceutical development towards enhancing treatment specificity and safety by focusing on reducing off-target effects.",
      "gt_sources": [
        "Target-18336052",
        "drugbank-drug"
      ],
      "system_sources": [
        "drugbank-drug_pharmacology.csv",
        "pubmed-targets/Target-10223928",
        "pubmed-targets/Target-15665994",
        "pubmed-targets/Target-12614192"
      ],
      "metrics": {
        "rouge1": 0.40718562874251496,
        "rouge2": 0.14545454545454545,
        "rougeL": 0.251497005988024,
        "string_similarity": 0.01485148514851485,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 34.56135964393616,
        "llm_correctness": 0.8
      }
    },
    {
      "question": "What is the proposed mechanism by which salmeterol achieves its long duration of action in asthma treatment, and is this mechanism associated with any specific biological targets?",
      "gt_answer": "Salmeterol achieves its long duration of action in asthma treatment by binding with high affinity to the beta2-adrenergic receptor (beta 2AR) and potentially to a secondary site termed the \"exosite.\" However, the specific targets listed in the drugbank-targets table do not include beta2-adrenergic receptor, as they are primarily associated with drugs like Cetuximab and Lepirudin, which target different proteins such as the Epidermal growth factor receptor and Prothrombin, respectively.",
      "system_answer": "Salmeterol achieves its long duration of action in asthma treatment primarily through its selective interaction with beta 2-adrenergic receptors. This interaction leads to prolonged bronchodilation by relaxing bronchial smooth muscle. Although the documents do not specify the exact mechanism for salmeterol, the comparison with formoterol, another long-acting beta 2-agonist, suggests a similar pharmacodynamic effect related to sustained receptor activation.",
      "gt_sources": [
        "Target-10471277",
        "drugbank-targets"
      ],
      "system_sources": [
        "pubmed-targets/Target-10714305",
        "pubmed-targets/Target-14971821",
        "pubmed-targets/Target-30218717",
        "pubmed-targets/Target-9506248",
        "pubmed-targets/Target-25096913"
      ],
      "metrics": {
        "rouge1": 0.3880597014925373,
        "rouge2": 0.16666666666666666,
        "rougeL": 0.28358208955223885,
        "string_similarity": 0.23789473684210527,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 34.568562507629395,
        "llm_correctness": 0.7
      }
    },
    {
      "question": "How does the mechanism of action of salmeterol compare to the type of drugs commonly used for similar purposes?",
      "gt_answer": "Salmeterol is a long-acting beta2-adrenergic receptor agonist used for asthma, whereas the drugs listed in the drugbank-drug table, such as Lepirudin and Etanercept, are biotech drugs with different mechanisms, focusing on anticoagulation and tumor necrosis factor inhibition, respectively. These drugs are produced biotechnologically, unlike salmeterol, which is a small molecule drug.",
      "system_answer": "Salmeterol, like formoterol, is a selective beta 2-adrenoceptor agonist used for prolonged bronchodilation in patients with asthma and COPD. While both drugs offer extended bronchodilation, formoterol achieves bronchodilation more rapidly than salmeterol. Unlike shorter-acting beta 2-agonists such as salbutamol, salmeterol provides advantages in treating nocturnal and exercise-induced asthma due to its long duration of action. It is often used alongside inhaled corticosteroids to manage asthma and COPD symptoms.",
      "gt_sources": [
        "Target-10471277",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-10714305",
        "pubmed-targets/Target-14971821",
        "pubmed-targets/Target-9506248",
        "pubmed-targets/Target-17407276",
        "pubmed-targets/Target-25096913"
      ],
      "metrics": {
        "rouge1": 0.3015873015873016,
        "rouge2": 0.06451612903225806,
        "rougeL": 0.20634920634920634,
        "string_similarity": 0.053156146179401995,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 13.88894248008728,
        "llm_correctness": 0.5
      }
    },
    {
      "question": "Is there any information about the synthesis or FDA labeling of salmeterol, and how does this relate to the research described?",
      "gt_answer": "The drugbank-drug table includes synthesis references and FDA labeling for some drugs, but not for salmeterol specifically. The passage describes the design and synthesis of a photoaffinity label for salmeterol ([125I]IAS), indicating advanced research efforts, yet this specific synthesis detail is not covered in the table entries, which focus on other drugs like Etanercept and Lepirudin.",
      "system_answer": "The provided documents do not contain any specific information about the synthesis or FDA labeling of salmeterol. They mainly cover details about other drugs and related topics. To find relevant information on salmeterol's synthesis or FDA labeling, it would be necessary to consult pharmacological databases or FDA resources directly.",
      "gt_sources": [
        "Target-10471277",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-10714305",
        "pubmed-targets/Target-14971821",
        "drugbank-drugs_links.csv",
        "drugbank-drug_mixtures.csv",
        "pubmed-targets/Target-9506248",
        "drugbank-drug_targ_attachments.csv",
        "pubmed-targets/Target-25096913"
      ],
      "metrics": {
        "rouge1": 0.3333333333333333,
        "rouge2": 0.03773584905660378,
        "rougeL": 0.2037037037037037,
        "string_similarity": 0.07713498622589532,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 128.09941220283508,
        "llm_correctness": 0.8
      }
    },
    {
      "question": "How does loperamide's mechanism of action in rodent models relate to its classification as a drug?",
      "gt_answer": "Loperamide acts by stimulating [35S]guanosine-5'-O-(3-thio)triphosphate binding and inhibiting forskolin-stimulated cAMP accumulation in rodent models, indicating its role as an opioid receptor agonist. However, loperamide itself is not listed in the drugbank-drug table, which primarily includes biotech drugs like lepirudin and cetuximab, suggesting loperamide might be classified differently or is missing from this specific dataset.",
      "system_answer": "The provided documents do not contain specific information about loperamide's mechanism of action in rodent models or its classification as a drug. While they discuss mechanisms of action for other drugs, such as opioid receptor activity and peripheral action, there is no direct information on loperamide. Therefore, the relationship between loperamide's mechanism of action in rodent models and its classification cannot be determined from these documents.",
      "gt_sources": [
        "Target-10087042",
        "drugbank-drug"
      ],
      "system_sources": [
        "pubmed-targets/Target-8133056",
        "pubmed-targets/Target-17850768",
        "pubmed-targets/Target-17504220",
        "pubmed-targets/Target-19557097",
        "pubmed-targets/Target-476986",
        "pubmed-targets/Target-15355124",
        "pubmed-targets/Target-19225726",
        "pubmed-targets/Target-2137975",
        "pubmed-targets/Target-10471277"
      ],
      "metrics": {
        "rouge1": 0.3384615384615384,
        "rouge2": 0.04687500000000001,
        "rougeL": 0.19999999999999998,
        "string_similarity": 0.0044742729306487695,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 59.9762020111084,
        "llm_correctness": 0.5
      }
    },
    {
      "question": "What target proteins are associated with the drugs in the study, and how does diclofenac's mechanism relate to these targets?",
      "gt_answer": "The passage describes diclofenac's effect on prostaglandin E2 and thromboxane B2, which are indicators of COX-2 and COX-1 activity. While the passage focuses on diclofenac, the related tables mention targets such as the epidermal growth factor receptor for other drugs like Cetuximab. Diclofenac, however, is known to work by inhibiting COX enzymes, which is not directly related to the targets listed in the tables.",
      "system_answer": "The target proteins associated with the drugs in the study include cyclooxygenase (COX) enzymes for diclofenac, estrogen receptors (ERalpha and ERbeta) for tamoxifen, serotonin and dopamine reuptake transporters for sertraline, and HIV protease for protease inhibitors like saquinavir, indinavir, and ritonavir. Diclofenac's mechanism relates to these targets through its inhibition of COX enzymes, which are responsible for prostaglandin synthesis, thus reducing inflammation and pain.",
      "gt_sources": [
        "Target-12534640",
        "drugbank-targets"
      ],
      "system_sources": [
        "pubmed-targets/Target-19843061",
        "pubmed-targets/Target-9297727",
        "pubmed-targets/Target-18664165",
        "pubmed-targets/Target-25088930",
        "pubmed-targets/Target-8566109",
        "pubmed-targets/Target-8937457",
        "pubmed-targets/Target-12446609",
        "pubmed-targets/Target-16326830",
        "pubmed-targets/Target-11587492",
        "pubmed-targets/Target-17852022"
      ],
      "metrics": {
        "rouge1": 0.3787878787878788,
        "rouge2": 0.12307692307692308,
        "rougeL": 0.18181818181818182,
        "string_similarity": 0.04656319290465632,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 67.71599650382996,
        "llm_correctness": 0.5
      }
    }
  ],
  "aggregate_metrics": {
    "rouge1": {
      "mean": 0.4131512008310046,
      "median": 0.3763098272444067,
      "min": 0.2978723404255319,
      "max": 0.6666666666666666,
      "std": 0.10022973445057859
    },
    "rouge2": {
      "mean": 0.17123865048505094,
      "median": 0.1595238095238095,
      "min": 0.02666666666666666,
      "max": 0.4857142857142857,
      "std": 0.11758345214919691
    },
    "rougeL": {
      "mean": 0.2959929812167955,
      "median": 0.26927190456602224,
      "min": 0.15584415584415587,
      "max": 0.5833333333333334,
      "std": 0.10818652559192958
    },
    "string_similarity": {
      "mean": 0.1541983402275973,
      "median": 0.10046284501061571,
      "min": 0.0044742729306487695,
      "max": 0.5121412803532008,
      "std": 0.1385919925403358
    },
    "source_precision": {
      "mean": 0.01,
      "median": 0.0,
      "min": 0.0,
      "max": 0.2,
      "std": 0.04358898943540674
    },
    "source_recall": {
      "mean": 0.025,
      "median": 0.0,
      "min": 0.0,
      "max": 0.5,
      "std": 0.10897247358851682
    },
    "source_f1": {
      "mean": 0.014285714285714287,
      "median": 0.0,
      "min": 0.0,
      "max": 0.28571428571428575,
      "std": 0.062269984907723924
    },
    "llm_correctness": {
      "mean": 0.5950000000000001,
      "median": 0.75,
      "min": 0.0,
      "max": 1.0,
      "std": 0.33834154341434336
    }
  }
}